Certuity LLC Has $775,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Certuity LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 44.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,395 shares of the biopharmaceutical company’s stock after acquiring an additional 2,574 shares during the period. Certuity LLC’s holdings in Gilead Sciences were worth $775,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. nVerses Capital LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth about $25,000. HHM Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the 4th quarter worth about $28,000. Finally, Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock opened at $96.14 on Wednesday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51. The firm’s 50 day moving average is $93.07 and its 200-day moving average is $86.99. The firm has a market capitalization of $119.82 billion, a price-to-earnings ratio of 1,068.22, a PEG ratio of 1.25 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Sell-side analysts forecast that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on GILD. Oppenheimer boosted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Bank of America restated a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Finally, BMO Capital Markets upped their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock worth $53,611,715. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.